Transthyretin Amyloidosis Treatment Market Analysis

Based on the type, the global market is classified into ATTR amyloidosis with cardiomyopathy (ATTR-CM) and ATTR amyloidosis with polyneuropathy (ATTR-PN). The ATTR-CM dominated the market with revenue of USD 4.7 billion in 2023.

• ATTR-CM is a form of amyloidosis characterized by the deposition of abnormal transthyretin protein in the heart, leading to heart failure. This segment's prominence is driven by the rising prevalence of ATTR-CM, coupled with advancements in diagnostics techniques that aid in timely intervention.

   

• Further, the development of novel therapeutics, including gene silencing therapies and stabilizers of transthyretin protein has also fueled the growth of this segment.

   

• Additionally, increasing awareness among healthcare professionals and patients about the disease and its treatment options has contributed to the ATTR-CM segment's high market share.

Based on disease type, the transthyretin amyloidosis treatment market is classified into hereditary transthyretin amyloidosis and wild type transthyretin amyloidosis. The hereditary transthyretin amyloidosis is further segmented into polyneuropathy, cardiomyopathy, and mixed type. The segment held a dominant business share of 61.7% in 2023.

• Hereditary transthyretin amyloidosis (hATTR) holds a significant market share in the market, driven by its genetic predisposition and progressive nature. hATTR is the most common form of transthyretin amyloidosis, accounting for a significant majority of cases. This prevalence increases the demand for targeted therapies specific to hATTR.

   

• Additionally, the genetic nature of hATTR necessitates long-term treatment, further driving the segment growth.

   

• Moreover, the severity and progressive nature of hATTR, often leads to debilitating neuropathy and cardiac complications, emphasizing the urgent need for effective treatments, spurring research and development efforts in this area.

   

Based on drug type, the transthyretin amyloidosis treatment market is classified into tafamidis, patisiran, inotersen, and other drug types. The tafamidis segment is expected to hold the highest revenue throughout the forecast period.

• High market share of tafamidis drug can be attributed to its high efficacy and safety profile. It works by stabilizing the transthyretin protein, preventing its breakdown into amyloid fibrils, and thereby slowing the progression of the disease.

   

• The drug's success in clinical trials, coupled with its approval by regulatory bodies around the world, has made it a cornerstone in the management of transthyretin amyloidosis, contributing to its high market share in the treatment landscape.

   

Based on route of administration, the transthyretin amyloidosis treatment market is classified into oral and parenteral. The oral segment is anticipated to grow at a CAGR of 7.2% between 2024 – 2032.

• Oral medications offer convenience and ease of administration, leading to better patient compliance and treatment outcomes.

   

• Additionally, oral medications have a more favorable safety profile compared to other treatment modalities, reducing the risk of adverse events.

   

• The development of novel oral therapies targeting transthyretin amyloidosis has further boosted the growth of this segment, providing patients with more treatment options, and potentially improving their quality of life.

   

Based on distribution channel, the transthyretin amyloidosis treatment market is classified into hospital pharmacy, retail drug stores, and online pharmacy. The hospital pharmacy segment is expected to be valued at USD 5 billion by 2032.

• High segment growth is primarily fueled by the well-equipped nature of the hospital pharmacies to handle these specialized medications, ensuring that patients receive the exact formulations prescribed by their healthcare providers.

   

• Moreover, hospital pharmacies are staffed by pharmacists with clinical expertise who work closely with healthcare providers to ensure accurate and safe medication management for patients with complex condition of transthyretin amyloidosis.

   

• Further, high volume of patients visiting hospitals, drives the segmental growth of hospital pharmacy segment.

In 2023, North America held a market share of 37.6% in the global transthyretin amyloidosis treatment and is expected to dominate throughout the forecast period.

• The region boasts of a well-established healthcare infrastructure, high awareness about rare diseases among healthcare professionals and patients, and robust reimbursement policies. Additionally, the presence of key market players and ongoing research and development activities contribute to the growth of this market in North America.

   

• Further, the region's strong focus on innovation and early adoption of advanced therapies further enhances its market share in transthyretin amyloidosis treatment.